We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+14.61%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$823M
AUM Growth
+$108M
Cap. Flow
+$78M
Cap. Flow %
9.48%
Top 10 Hldgs %
55.91%
Holding
41
New
6
Increased
14
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
BLFS icon
BioLife Solutions
BLFS
+$28.3M
2
NVTA
Invitae Corporation
NVTA
+$27.3M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$17.3M
4
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$14.5M
5
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$12.5M

Top Sells

Rank Stock Value
1
FMI
Foundation Medicine, Inc.
FMI
+$93.6M
2
ZLAB icon
Zai Lab
ZLAB
+$3.14M
3
OSUR icon
OraSure Technologies
OSUR
+$1.88M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$1.77M
5
FATE icon
Fate Therapeutics
FATE
+$591K

Sector Composition

Rank Sector Weight
1 Healthcare 86.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OSUR icon
26
OraSure Technologies
OSUR
$286M
$8.11M 0.99%
525,000
-115,000
-18% -$1.88M
QTTB icon
27
Q32 Bio
QTTB
$450M
$8M 0.97%
19,444
+13,055
+204% +$4.43M
CLVS
28
DELISTED
Clovis Oncology, Inc.
CLVS
$6.9M 0.84%
235,000
+15,000
+7% +$581K
SRPT icon
29
Sarepta Therapeutics
SRPT
$1.68B
$6.46M 0.79%
+40,000
New +$5.47M
CDNA icon
30
CareDx
CDNA
$2.48B
$5.77M 0.7%
200,000
– –
NEOG icon
31
Neogen
NEOG
$2.59B
$4.65M 0.57%
130,000
– –
CELG
32
CALL
DELISTED
Celgene Corp
CELG
$4.47M 0.54%
+50,000
New +$4.42M
GILD icon
33
CALL
Gilead Sciences
GILD
$163B
$3.86M 0.47%
+50,000
New +$3.78M
CTMX icon
34
CytomX Therapeutics
CTMX
$690M
$3.84M 0.47%
207,500
– –
NTGN
35
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
$2.89M 0.35%
338,345
– –
JNCE
36
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$2.44M 0.3%
375,000
– –
BPMC
37
CALL
DELISTED
Blueprint Medicines
BPMC
– –
-10,000
Closed -$635K
ZLAB icon
38
Zai Lab
ZLAB
$2.05B
– –
-135,000
Closed -$3.14M
GBT
39
PUT
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-50,000
Closed -$2.26M
LOXO
40
PUT
DELISTED
Loxo Oncology, Inc
LOXO
– –
-20,000
Closed -$3.47M
FMI
41
DELISTED
Foundation Medicine, Inc.
FMI
– –
-685,000
Closed -$93.6M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q3 2018 Portfolio in Review

As of Q3 2018, Casdin Capital held 41 positions worth $823M, up 15% from $715M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Casdin Capital deployed $78M of net new capital in Q3 2018, opening 6 new positions and adding to 14 existing holdings. Its largest new stake was Invitae Corporation: 2,400,000 shares worth $40.2M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 91% a quarter earlier.

On the sell side, the largest reduction was OraSure Technologies, an estimated $1.88M trimmed.

  • Casdin Capital's largest Q3 2018 buy was Invitae Corporation: 2,400,000 shares worth $40.2M.
  • Casdin Capital added most to BioLife Solutions in Q3 2018, an estimated $28.3M increase.
  • Casdin Capital's biggest Q3 2018 reduction was OraSure Technologies, cutting an estimated $1.88M.
  • Casdin Capital fully exited Foundation Medicine, Inc. in Q3 2018, selling an estimated $93.6M.
  • Casdin Capital's ten largest holdings make up 56% of its $823M portfolio in Q3 2018.
  • Casdin Capital opened 6 new positions and closed 5 in Q3 2018.
  • Casdin Capital's portfolio value rose 15% quarter-over-quarter to $823M.

Based on Casdin Capital's 13F filing for Q3 2018, filed 14 Nov 2018.